Abstract
AbstractOral PrEP’s effectiveness relies on adequate adherence during periods of substantial HIV risk. Since most PrEP users will miss doses, understanding predictors within participants can help to explain adherence. We used a cross-sectional, within-participant design with 67 gay, bisexual, and other men who have sex with men taking PrEP daily. Using a questionnaire, informed by the Information Motivation Behavioral Skills Model, participants were asked about an adherent and a non-adherent episode. PrEP non-adherence was associated with non-normality of the day (p < .001), being out of the home (p < .001), weekend days (p = .01), having company (p = .02), using substances (p = 0.02), not using reminders (p = .03), lower PrEP information (p = .04), lower behavioural skills (p < .001) and less positive affect (p = .002). PrEP adherence assessment could focus on situational variations, supporting the construction of alternative strategies to facilitate adherence in these situations.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,Social Psychology
Reference74 articles.
1. European Centre for Disease Prevention and Control and WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2021–2020 data. Copenhagen: WHO Regional Office for Europe.; 2021 [Available from: https://www.ecdc.europa.eu/en/publications-data/hiv-aids-surveillance-europe-2021-2020-data] (Accessed 21 April 2022).
2. UK Health Security Agency. HIV testing, new HIV diagnoses, outcomes and quality of care for people accessing HIV services: 2021 report. London: UK Health Security Agency.; 2021 [available at: https://www.gov.uk/government/statistics/hiv-annual-data-tables (Accessed 21 April 2022].
3. Brizzi F, Birrell PJ, Kirwan P, Ogaz D, Brown AE, Delpech VC, et al. Tracking elimination of HIV transmission in men who have sex with men in England: a modelling study. The Lancet HIV. 2021;8(7):e440–e8.
4. Mujugira A, Baeten JM, Hodges-Mameletzis I, Haberer JE. Lamivudine/Tenofovir Disoproxil Fumarate is an appropriate PrEP regimen. Drugs. 2020;80(18):1881–8.
5. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–83.